Inducing Immune Quiescence to Prevent HIV Infection in Women
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
In this project, the investigators want to analyse the capacity of Acetylsalicylic acid and
hydoxychlroquin (HCQ) to induce an Immune Quiescence (IQ) phenotype, which has been
previously associated with natural protection to HIV infection. This phenotype is
characterized by lower expression of genes involved in cellular activation, lower resting
levels of inflammatory cytokine production, lower level of systemic activated T cells,
increased levels of systemic T regulatory, increased production of anti-viral anti-protease
serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+
CCR5+ T cells) in the FGT ( female genital tract).
The objective of this study is to determine if daily oral administration of Acetylsalicylic
acid or hydroxychlroroquin can reduce systemic and mucosal immune activation in HIV negative
women.